LLC1

• Description:

  LLC1 is an Amiloride (HY-B0285) derivative with cytotoxicity against breast cancer cells, particularly those resistant to treatment. The IC50 values of LLC1 for MCF7, MCF7 MX-100, MCF7 TS, MCF7 TR-1, and MCF7 TR-5 are 13, 12, 25, 26, and 19 mM, respectively. LLC1 shows potential for research in the field of cancer therapy[1].

• UNSPSC:

  12352005

• Target:

  Drug Derivative

• Type:

  Reference compound

• Related Pathways:

  Others

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/llc1.html

• Smiles:

  N/C(N)=N\C(C1=C(N=C(C(Cl)=N1)N2CCC(CC2)C3=CC=C(C=C3)F)N)=O

• Molecular Formula:

  C17H19ClFN7O

• Molecular Weight:

  391.83

• References & Citations:

  [1]Hu M, et al. A novel lipophilic amiloride derivative efficiently kills chemoresistant breast cancer cells. Sci Rep. 2024 Aug 31;14 (1) :20263.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported